Jump to ContentJump to Main Navigation
Show Summary Details
More options …

The EuroBiotech Journal


4 Issues per year

Open Access
See all formats and pricing
More options …

Biomarkers development for early detection of cancer: Reducing the burden of cancer in the ageing society

Laura Paneghetti / Andrea Gallotta / Chiara Parrozzani / Giorgio Fassina
Published Online: 2018-02-06 | DOI: https://doi.org/10.2478/ebtj-2018-0005


The ageing process in the European society will become one of the key driving forces of change over the next decades. The specific demands of older generations constitute a key market of the future, and the pressure to improve and expand health services increases, especially as far as chronic diseases, such as cancer. Availability of cost effective cancer early detection protocols, based on predictive biomarkers, will improve patients management reducing consequently the high costs associated to treating patients when the disease is at an advanced stage.

Keywords: biomarkers; cancer; health technology assessment (HTA); hepatocellular carcinoma; chronic hepatitis C; cirrhosis


  • 1. American Cancer Society, Global Cancer Facts & Figures 3rd Edition. 2015, American Cancer Society: Atlanta.Google Scholar

  • 2. National Cancer Institute. Probability of Developing or Dying of Cancer. 2015 [cited 2016] ; Available from: srab.cancer.gov/devcan.Google Scholar

  • 3. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncology. 2012. 13: 790-801.Google Scholar

  • 4. Vollmers HP, Brandlein S. Natural antibodies and cancer. Journal of Autoimmunity. 2007. 29(4): 295-302.CrossrefGoogle Scholar

  • 5. Beneduce L, Prayer-Galletti T, Marcello Grimani Giustinian A, Gallotta A, Betto G, Pagano F, Fassina G. Detection of prostate specific antigen coupled to immunoglobulin M In prostate cancer patients. Cancer Detection and Prevention. 2007. 31: 402-407.Google Scholar

  • 6. Castaldi F, Marino M, Beneduce L, Belluco C, De Marchi F, Mammano E, Nitti D, Lise M, Fassina G. Detection of circulating CEA-IgM complexes in early stage colorectal cancer. International Journal of Biological Markers. 2005. 20(4): 204-208.CrossrefGoogle Scholar

  • 7. Beneduce L, Castaldi F, Marino M, Quarta S, Ruvoletto M, Benvegnù L, Calabrese F, Gatta A, Pontisso P, Fassina G. Squamous cell carcinoma antigen-Immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer. 2005. 103: 2558-2565.Google Scholar

  • 8. Beneduce L, Castaldi F, Marino M, Tono N, Gatta A, Pontisso P, Fassina G. Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes. International Journal of Biological Markers. 2004. 19: 155-159.Google Scholar

  • 9. Beneduce L, Pesce G, Gallotta A, Zampieri F, Biasiolo A, Tono N, Boscato N, Gatta A, Pontisso P, Fassina G. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma. European Journal of Clinical Investigation. 2008. 38: 571-577.Google Scholar

  • 10. Martini A, Gallotta A, Pontisso P, Fassina G. Clinical applications of squamous cell carcinoma antigen_immunoglobulins M to monitor chronic hepatitis C. World Journal of Hepatology. 2015. 7(29): 2913-2919.Google Scholar

  • 11. Biggins SW, Bambha KM, Terrault NA, Inadomi J, Shiboski S, Dodge JL, Gralla J, Rosen HR, Roberts JP. Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transplantation. 2012. 18: 1471-1478.CrossrefWeb of ScienceGoogle Scholar

  • 12. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010. 138: 513-521.Google Scholar

  • 13. World Health Organization, World report on aging and health. 2015.Google Scholar

  • 14. EASL-EORTC. Clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology. 2012. 56: 908-943.Google Scholar

  • 15. Bruix J,Sherman M. Management of hepatocellular carcinoma: an update.Hepatology. 2011. 53(3): 1020-1022.CrossrefWeb of ScienceGoogle Scholar

  • 16. Biasiolo A, Chemello L, Quarta S, Cavalletto L, Bortolotti F, Caberlotto C, Beneduce L, Bernardinello E, Tono N, Fassina G, Gatta A, Pontisso P. Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis. Journal of Viral Hepatitis. 2008. 15: 246-249.CrossrefWeb of ScienceGoogle Scholar

  • 17. Pontisso P,Quarta S, Caberlotto C, Beneduce L, Marino M, Bernardinello E, Tono N, Fassina G, Cavalletto L, Gatta A, Chemello L. Progressive increse of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. International Journal of Cancer. 2006. 119: 735-740.Google Scholar

  • 18. Biasiolo A, Trotta E, Fasolato S, Ruvoletto M, Martini A, Gallotta A, Fassina G, Angeli P, Gatta A, Pontisso P. Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study.Digestive Liver Disease. 2016. 48(2): 197-202.Google Scholar

  • 19. Buccione D, Fatti G, Gallotta A, Loggi E, Di Donato R, Testa L, Saitta C, Santi V, Di Micoli A, Erroi V, Frigerio M, Fazio V, Picciotto A, Biasiolo A, Degos F, Pontisso P, Raimondo G, Trevisani F. Serum SCCA-IgM as a predictor of hepatocellular carcinoma in patients with cirrhosis. Open Journal of Gastroenterology. 2012. 2: 56-61.Google Scholar

  • 20. Morisco F,Guarino M, Di Costanzo GG, Gallotta A, Fassina G, Tortora R, Tuccillo C, Granata R, Loperto I, Auriemma F, Caporaso N. Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in HCC patients. Journal of Hepatology. 2015. 62(S450).Web of ScienceGoogle Scholar

  • 21. Giannelli G, Fransvea E, Trerotoli P, Beaugrand M, Marinosci F, Lupo L, Nkontchou G, Dentico P, Antonaci S. Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clinica Chimica Acta. 2007. 383: 147-152.Web of ScienceGoogle Scholar

  • 22. Crescenzi M, Tessari A, Biasiolo A, Padoan A, Gallotta A, Fassina G, Panciatichi C, Rossetto O, Pontisso P, Basso D, Plebani M. Analytical Validation of a biochip prototype for integrated analysis of AFPIgM and SCCA-IgM serum biomarkers in patients with liver cirrhosis and hepatocellular carcinoma.Analytical Methods. 2015(2): 626-637.Google Scholar

  • 23. Gil-Gómez A, Ampuero J, Gallego-Durán R, Fassina G, Pontisso P, Romero-Gomez M. SCCA-IgM helps to identify patients at risk of long-term hepatocellular carcinoma.Hepatology. 2016. 64(S1): 656A.Google Scholar

  • 24. Regione Veneto. Tariffario delle Prestazioni Specialistiche Ambulatoriali.Google Scholar

  • 25. AIRTUM-AIOM, I numeri del cancro in Italia. 2016.Google Scholar

  • 26. Giannini EG,Cucchetti A, Erroi V, Garuti F, Odaldi F, Trevisani F. Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it? World Journal of Gastroenterology. 2013. 19(47): 8808-8821.Web of ScienceGoogle Scholar

  • 27. Thompson Coon J,Rogers G, Hewson P, Wright D, Anderson R, Jackson S, Ryder S, Cramp M, Stein K. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. British Journal of Cancer. 2008. 98: 1166-1175.Web of ScienceCrossrefGoogle Scholar

About the article

Published Online: 2018-02-06

Published in Print: 2018-01-01

Citation Information: The EuroBiotech Journal, Volume 2, Issue 1, Pages 30–34, ISSN (Online) 2564-615X, DOI: https://doi.org/10.2478/ebtj-2018-0005.

Export Citation

© 2018. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License. BY-NC-ND 4.0

Comments (0)

Please log in or register to comment.
Log in